Intravenous Immunoglobulin and Anti-RhD Therapy in the Management of Immune Thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 23, Issue 6, 2009, Pages 1317-1327

  Cooper, Nichola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

FcRIIb; Immunemodulation; ITP; IV anti D; IVIG; Thrombocytopenia

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DANAZOL; FC RECEPTOR; FC RECEPTOR IIB; IMMUNOGLOBULIN; PARACETAMOL; PREDNISOLONE; PREDNISONE; RHESUS D ANTIBODY;

ANEMIA; ARTHRALGIA; AUTOIMMUNE THROMBOCYTOPENIA; BACKACHE; CHILL; CLINICAL TRIAL; DENDRITIC CELL; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEART INFARCTION; HEMOGLOBINURIA; HUMAN; INJECTION SITE REACTION; INTRAVASCULAR HEMOLYSIS; KIDNEY FAILURE; LUNG EDEMA; MACROPHAGE; MYALGIA; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RESPIRATORY DISTRESS; REVIEW; SINGLE DRUG DOSE; SPLENECTOMY; STROKE; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RHO(D) IMMUNE GLOBULIN;

EID: 70449678715     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.09.002     Document Type: Review

References (58)

1. Imbach P., Barandun S., Baumgartner C., et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 36 (1981) 81-86
2. Wagner H.P., Barandun S., Hirt A., et al. High-dose immunoglobulin infusions in idiopathic thrombopenic purpura. Presse Med 12 (1983) 2612-2614 [in French]
3. Bussel J.B., and Hilgartner M.W. The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Br J Haematol 56 (1984) 1-7
4. Bussel J.B., and Szatrowski T.P. Uses of intravenous gammaglobulin in immune hematologic disease. Immunol Invest 24 (1995) 451-456
5. Kurlander R., Coleman R.E., Moore J., et al. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med 83 (1987) 17-24
6. Godeau B., Lesage S., Divine M., et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 82 (1993) 1415-1421
7. Bussel J.B. Splenectomy-sparing strategies for the treatment and long-term maintenance of chronic idiopathic (immune) thrombocytopenic purpura. Semin Hematol 37 (2000) 1-4
8. Bussel J.B., Pham L.C., Aledort L., et al. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood 72 (1988) 121-127
9. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 28 Suppl 1 (2008) S42-S45
10. Michel M., Chanet V., Galicier L., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 83 (2004) 254-263
11. Bussel J.B., Schulman I., Hilgartner M.W., et al. Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. J Pediatr 103 (1983) 651-654
12. Blanchette V., Imbach P., Andrew M., et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344 (1994) 703-707
13. Beck C.E., Nathan P.C., Parkin P.C., et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 147 (2005) 521-527
14. Tamminga R., Berchtold W., Bruin M., et al. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). Br J Haematol 146 (2009) 180-184
15. Lefrere J.J., Loiseau P., Martinot-Peignoux M., et al. Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion 36 (1996) 394-397
16. Pawlotsky J.M., Bouvier M., Deforges L., et al. Chronic hepatitis C after high-dose intravenous immunoglobulin. Transfusion 34 (1994) 86-87
17. Salama A., Kiefel V., Amberg R., et al. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)). Blut 49 (1984) 29-35
18. Becker T., Kuenzlen E., Salama A., et al. Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D). Eur J Pediatr 145 (1986) 166-169
19. Salama A., Kiefel V., and Mueller-Eckhardt C. Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol 22 (1986) 241-250
20. Scaradavou A., Woo B., Woloski B.M., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 89 (1997) 2689-2700
21. Newman G.C., Novoa M.V., Fodero E.M., et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 112 (2001) 1076-1078
22. Tarantino M.D., Young G., Bertolone S.J., et al. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 148 (2006) 489-494
23. Cooper N., Heddle N.M., Haas M., et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol 124 (2004) 511-518
24. Cooper N., Woloski B.M., Fodero E.M., et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. Blood 99 (2002) 1922-1927
25. Scaradavou A., Cunningham-Rundles S., Ho J.L., et al. Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. Am J Hematol 82 (2007) 335-341
26. Bussel J.B., Graziano J.N., Kimberly R.P., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 77 (1991) 1884-1893
27. Michel M., Novoa M.V., and Bussel J.B. Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol 123 (2003) 142-146
28. Cromwell C., Tarantino M., and Aledort L.M. Safety of anti-D during pregnancy. Am J Hematol 84 (2009) 261-262
29. Gaines A.R. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 95 (2000) 2523-2529
30. Gaines A.R. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 106 (2005) 1532-1537
31. Fehr J., Hofmann V., and Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306 (1982) 1254-1258
32. Newland A.C., and Macey M.G. Immune thrombocytopenia and Fc receptor-mediated phagocyte function. Ann Hematol 69 (1994) 61-67
33. Siragam V., Brinc D., Crow A.R., et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?. J Clin Invest 115 (2005) 155-160
34. Clarkson S.B., Bussel J.B., Kimberly R.P., et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 314 (1986) 1236-1239
35. Song S., Crow A.R., Freedman J., et al. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 101 (2003) 3708-3713
36. Kurlander R.J. Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. J Immunol 131 (1983) 140-147
37. Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98 (2001) 1095-1099
38. Smith N.A., and Boughton B.J. The treatment of autoimmune thrombocytopaenic purpura with anti-D immunoglobulin: similar platelet responses in homozygous and heterozygous Rh(D) positive patients. Transfus Med 1 (1991) 183-185
39. Soubrane C., Tourani J.M., Andrieu J.M., et al. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood 81 (1993) 15-19
40. Burdach S.E., Evers K.G., and Geursen R.G. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations. J Pediatr 109 (1986) 770-775
41. Tovo P.A., Miniero R., Fiandino G., et al. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr 105 (1984) 676-677
42. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
43. Crow A.R., Song S., Freedman J., et al. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102 (2003) 558-560
44. Crow A.R., Song S., Siragam V., et al. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 47 (2006) 710-713
45. Bruhns P., Samuelsson A., Pollard J.W., et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18 (2003) 573-581
46. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
47. Anthony R.M., Wermeling F., Karlsson M.C., et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 105 (2008) 19571-19578
48. Siragam V., Crow A.R., Brinc D., et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12 (2006) 688-692
49. Crow A.R., Brinc D., and Lazarus A.H. New insight into the mechanism of action of IVIg: the role of dendritic cells. J Thromb Haemost 7 Suppl 1 (2009) 245-248
50. Newland A.C., Macey M.G., and Veys P.A. Cellular changes during the infusion of high dose intravenous immunoglobulin. Blut 59 (1989) 82-87
51. Oksenhendler E., Bierling P., Brossard Y., et al. Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood 71 (1988) 1499-1502
52. Ramadan K.M., and El-Agnaf M. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. Clin Lab Haematol 27 (2005) 267-269
53. Malinowska I., Obitko-Pludowska A., Buescher E.S., et al. Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J 2 (2001) 242-249
54. Semple J.W., Allen D., Rutherford M., et al. Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. Am J Hematol 69 (2002) 225-227
55. Coopamah M.D., Freedman J., and Semple J.W. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood 102 (2003) 2862-2867
56. Crow A.R., Song S., Semple J.W., et al. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?. Blood 109 (2007) 155-158
57. Song S., Crow A.R., Siragam V., et al. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 105 (2005) 1546-1548
58. Podolanczuk A., Lazarus A.H., Crow A.R., et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113 (2009) 3154-3160